This is a randomized controlled trial in which the safety and feasibility of cell therapy
medicinal product shall be measured by comparing the variables of the response after
treatment compared to baseline prior to implementation. Secondarily the results obtained are
compared with each of the study groups.
Patients will receive concomitant basic pharmacological treatment for maintaining liver
All patients will be equally medically treated. The hypothetic test is to propose mononuclear
cells from the bone marrow infused in the territory hepatic portal remaining segments (II and
III) to be performed while contralateral portal embolization provides progenitor cells
hepatic regenerative capacity that would shorten the time of liver regeneration and increase
residual volume, facilitating the realization of an extended hepatectomy with greater
assurance of maintaining proper residual function and adequate surgical margins.